Department of Oncology, Bluewater Health, Sarnia, ON N7T 6S3, Canada.
Department of Family Medicine, Western University, London, ON N6A 3K7, Canada.
Curr Oncol. 2022 Apr 8;29(4):2539-2549. doi: 10.3390/curroncol29040208.
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), providing an actionable target for many different therapies. In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emtansine. In the third line setting and beyond, several emerging treatments have shown benefits, including novel small molecule targeted agents and antibody-drug conjugates. Systemic treatment of brain metastases in HER2-positive patients and the role of endocrine-based treatment for patients with hormone receptor (HR) positive disease remain areas of research interest. This article will review the current approach to systemic management of metastatic HER2-positive breast cancer in Canada, and present novel treatments that may be available in the near future.
大约 20%的乳腺癌过表达人表皮生长因子受体 2（HER2），为许多不同的治疗方法提供了一个可操作的靶点。在转移性环境中，曲妥珠单抗、帕妥珠单抗和曲妥珠单抗-美坦新偶联物等抗 HER2 药物的使用极大地改善了预后。在三线及以上治疗环境中，一些新出现的治疗方法显示出益处，包括新型小分子靶向药物和抗体药物偶联物。HER2 阳性患者脑转移的全身治疗以及激素受体（HR）阳性疾病的内分泌治疗的作用仍然是研究关注的领域。本文将回顾加拿大目前对转移性 HER2 阳性乳腺癌的全身治疗方法，并介绍近期可能出现的新治疗方法。
